The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Novel therapeutic for AML: fadraciclib combinations
Mhairi Copland, PhD, MBChB, FRCP, FRCPath, Paul O’Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, UK, outlines a study that aimed to assess the effects of fadraciclib, a novel CDK2/9 inhibitor, on the growth and survival of acute myeloid leukemia (AML) cells. The study also evaluated the synergistic effect of fadraciclib in combination with other targeted or chemotherapy agents. Results show that fadraciclib pulse treatment effectively induced apoptosis in AML cell lines in vitro and a synergistic effect of fadraciclib in combination with venetoclax, cytarabine or azacitidine was observed. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
